{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.4","upperLimit":"87.5","value":"82.96"},{"groupId":"OG001","lowerLimit":"84.2","upperLimit":"92.4","value":"88.30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"336"},{"groupId":"OG001","value":"323"}],"units":"Participants"}],"description":"Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event","dispersionType":"95% Confidence Interval","groups":[{"description":"No Nelarabine (Combined)","id":"OG000","title":"ARM I and ARM III (Combination Chemotherapy)"},{"description":"Nelarabine (Combined)","id":"OG001","title":"ARM II and ARM IV (Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Includes subjects randomized to Nelarabine versus No Nelarabine","reportingStatus":"POSTED","timeFrame":"4 years from randomization at the end of induction","title":"Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)","type":"PRIMARY","unitOfMeasure":"percent probability"}